TrialJournal of the American College of Cardiology2014

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

Michael J Koren et al.PubMed ↗Publisher ↗

No numbers read from the abstract.